A Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Coronavirus Disease 2019
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel β-coronavirus, causes severe pneumonia and has spread throughout the globe rapidly. The disease associated with SARS-CoV-2 infection is named coronavirus disease 2019 (COVID-19). To date, real-time reverse-transcription polymerase chain reaction (RT-PCR) is the only test able to confirm this infection. However, the accuracy of RT-PCR depends on several factors; variations in these factors might significantly lower the sensitivity of detection.
METHODS: In this study, we developed a peptide-based luminescent immunoassay that detected immunoglobulin (Ig)G and IgM. The assay cutoff value was determined by evaluating the sera from healthy and infected patients for pathogens other than SARS-CoV-2.
RESULTS: To evaluate assay performance, we detected IgG and IgM in the sera from confirmed patients. The positive rate of IgG and IgM was 71.4% and 57.2%, respectively.
CONCLUSIONS: Therefore, combining our immunoassay with real-time RT-PCR might enhance the diagnostic accuracy of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:222 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 222(2020), 2 vom: 29. Juni, Seite 189-193 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cai, Xue-Fei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 07.07.2020 Date Revised 18.12.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiaa243 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30966005X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30966005X | ||
| 003 | DE-627 | ||
| 005 | 20231225134414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiaa243 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM30966005X | ||
| 035 | |a (NLM)32382737 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cai, Xue-Fei |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Coronavirus Disease 2019 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.07.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel β-coronavirus, causes severe pneumonia and has spread throughout the globe rapidly. The disease associated with SARS-CoV-2 infection is named coronavirus disease 2019 (COVID-19). To date, real-time reverse-transcription polymerase chain reaction (RT-PCR) is the only test able to confirm this infection. However, the accuracy of RT-PCR depends on several factors; variations in these factors might significantly lower the sensitivity of detection | ||
| 520 | |a METHODS: In this study, we developed a peptide-based luminescent immunoassay that detected immunoglobulin (Ig)G and IgM. The assay cutoff value was determined by evaluating the sera from healthy and infected patients for pathogens other than SARS-CoV-2 | ||
| 520 | |a RESULTS: To evaluate assay performance, we detected IgG and IgM in the sera from confirmed patients. The positive rate of IgG and IgM was 71.4% and 57.2%, respectively | ||
| 520 | |a CONCLUSIONS: Therefore, combining our immunoassay with real-time RT-PCR might enhance the diagnostic accuracy of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a chemiluminescence immunoassay | |
| 650 | 4 | |a serological test | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Covid-19 aAPC vaccine |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 650 | 7 | |a Viral Proteins |2 NLM | |
| 700 | 1 | |a Chen, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Li Hu, Jie- |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Quan-Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Hai-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Pu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Bei-Zhong |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Gui-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yao-Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhi-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Kun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiao-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Wen-Guang |e verfasserin |4 aut | |
| 700 | 1 | |a Xiang, Jiang-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Hong-Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Ni |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Ji-Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Lu-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Gan, Chun-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yan-Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Qing-Zhu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, A-Mei |e verfasserin |4 aut | |
| 700 | 1 | |a He, Chang-Long |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Dao-Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Fa-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Ai-Long |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, De-Qiang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 222(2020), 2 vom: 29. Juni, Seite 189-193 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:222 |g year:2020 |g number:2 |g day:29 |g month:06 |g pages:189-193 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiaa243 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 222 |j 2020 |e 2 |b 29 |c 06 |h 189-193 | ||